UT San Antonio

Find a Clinical Trial


Filter by

  • Down Syndrome

    Diagnosis Requirements: Down Syndrome
    Age Eligibility: Adults diagnosed with Down Syndrome that can give verbal consent to participate.
    Medication: None

    Although nearly all people with Down syndrome have high levels of this brain pathology similar to Alzheimer’s, and their associated brain changes appear by the early age of 40, this population continues to be underserved when it comes to Alzheimer’s research.

  • image of three people sitting together outside setting

    The National Institute on Aging Family-Based Study

    Diagnosis Requirements: Two family members with symptoms or a diagnosis of Alzheimer's, mild cognitive impairment, dementia or a related diagnosis.
    Age Eligibility: Not applicable
    Medication: Not applicable

    Families with multiple members diagnosed with Alzheimer’s disease or related dementias are invited to join a national study focused on understanding the genetic risks associated with these conditions. Participation will provide invaluable insights that could significantly advance this crucial research.

  • Advancing Alzheimer’s Care: Home-Based tDCS for Affective Symptoms

    Diagnosis Requirements: Alzheimer's disease
    Age Eligibility: 60 years of age or older.
    Medication: Not applicable

    Alzheimer’s symptoms such as depression, anxiety, irritability and lack of motivation can significantly impact quality of life. A new research study is investigating an innovative approach to address these affective symptoms — using a portable, noninvasive brain stimulation device from the comfort of home.

  • Effect-AD Trial

    Diagnosis Requirements: Early/prodromal dementia with Lewy Body or mild cognitive impairment diagnosed with REM sleep behavior disorder.
    Age Eligibility: 50+ years old
    Medication: None

    Exploring how smart devices can help monitor daily activity and support individuals with early/prodromal Dementia with Lewy Body or mild cognitive impairment who have been diagnosed with REM sleep behavior disorder.

  • Psychosis Clinical Trials for Alzheimer’s Disease

    Diagnosis Requirements: Alzheimer’s disease
    Age Eligibility: Experienced symptoms of psychosis for at least one month.
    Medication: ITI-1284 or KarXT

    Researchers are studying medications that are FDA-approved for other conditions or have demonstrated safety in previous clinical use. These studies are designed to determine whether these treatments may also help reduce psychosis symptoms and improve overall well-being in individuals with Alzheimer’s.

  • Managing Agitation in Alzheimer’s Disease

    Diagnosis Requirements: Alzheimer's disease
    Age Eligibility: Experienced symptoms of agitation for at least two weeks.
    Medication: ITI-1284 or KarXT

    Researchers are studying medications that are FDA-approved for other conditions or have demonstrated safety in previous clinical use. These studies are designed to determine whether these treatments may also help reduce agitation symptoms and improve overall well-being in individuals with Alzheimer’s disease.